RESUMO
AIMS: Although nerolidol (NRL) is a naturally occurring sesquiterpene alcohol with many pharmacological activities, its role in dehydroepiandrosterone DHEA-induced polycystic ovary syndrome PCOS is unknown. This study aims to explore the potential beneficial effects and underlying molecular mechanisms of nerolidol treatment on polycystic ovary syndrome. MAIN METHODS: Pre-pubertal female Sprague-Dawley rats were randomly assigned into four groups (n = 8/group); group I: control; group II: PCOS; group III: P + NRL; group IV: NRL. Biochemical parameters related to oxidative stress, inflammation, apoptosis, and hormones were estimated in the blood and ovarian tissues. Histopathological, ultrastructural, and immunohistochemical analyses were performed. Bax, P53, Cas-3, and Bcl-2 gene expression levels were detected with RT-PCR. The membrane array analysis detected chemokine, cytokine, and growth factor protein profiles. KEY FINDINGS: In light of the available data, it can deduce that nerolidol has a significant ameliorating effect on lipid peroxidation, oxidative stress, inflammation, histopathological damage, and apoptosis accompanying PCOS in female rats. SIGNIFICANCE: PCOS is not only a reproductive pathology but also a systemic condition and its etiopathogenesis is still not fully understood. Since changes in PCOS have important long-term effects on health, this study evaluated the efficacy of nerolidol, a phytotherapeutic for the control of biochemical, apoptotic, histopathological, and metabolic changes.
Assuntos
Síndrome do Ovário Policístico , Sesquiterpenos , Humanos , Ratos , Feminino , Animais , Síndrome do Ovário Policístico/induzido quimicamente , Síndrome do Ovário Policístico/tratamento farmacológico , Síndrome do Ovário Policístico/genética , Ratos Sprague-Dawley , Sesquiterpenos/efeitos adversos , Estresse Oxidativo , Inflamação/tratamento farmacológico , Apoptose , Desidroepiandrosterona/uso terapêutico , Modelos Animais de DoençasRESUMO
Sesquiterpenes belong to the largest group of plant secondary metabolites, which consist of three isoprene building units. These compounds are widely distributed in various angiosperms, a few gymnosperms and bryophytes. Sesquiterpenes and their allied derivatives are bio-synthesized in various plant parts including leaves, fruits and roots. These plant-based metabolites are predominantly identified in the Asteraceae family, wherein up to 5000 complexes have been documented to date. Sesquiterpenes and their derivatives are characteristically associated with plant defence mechanisms owing to their antifungal, antibacterial and antiviral activities. Over the last two decades, these compounds have been reportedly demonstrated health promoting perspectives against a wide range of metabolic syndromes i.e. hyperglycemia, hyperlipidemia, cardiovascular complications, neural disorders, diabetes, and cancer. The high potential of sesquiterpenes and their derivatives against various cancers like breast, colon, bladder, pancreatic, prostate, cervical, brain, liver, blood, ovarium, bone, endometrial, oral, lung, eye, stomach and kidney are the object of this review. Predominantly, it recapitulates the literature elucidating sesquiterpenes and their derivatives while highlighting the mechanistic approaches associated with their potent anticancer activities such as modulating nuclear factor kappa (NF-kB) activity, inhibitory action against lipid peroxidation and retarding the production of reactive oxygen & nitrogen species (ROS&RNS).
Assuntos
Antineoplásicos Fitogênicos/uso terapêutico , Neoplasias/tratamento farmacológico , Sesquiterpenos/uso terapêutico , Animais , Antineoplásicos Fitogênicos/efeitos adversos , Feminino , Humanos , Masculino , Neoplasias/metabolismo , Neoplasias/patologia , Sesquiterpenos/efeitos adversos , Transdução de Sinais , Resultado do TratamentoRESUMO
Nicotinic acetylcholine receptor activation on the perivascular sympathetic nerves via axo-axonal interaction mechanism causes norepinephrine release, which triggers the neurogenic nitrergic relaxation in basilar arteries to meet the need of a brain. Donepezil and huperzine A, which are the cholinesterase inhibitors used for Alzheimer's disease therapy, exert controversial effects on nicotinic acetylcholine receptors. Therefore, we investigated how donepezil and huperzine A via the axo-axonal interaction regulate the neurogenic vasodilation of isolated porcine basilar arteries and define their action on different subtypes of the nicotinic acetylcholine receptor by using blood vessel myography, calcium imaging, and electrophysiological techniques. Both nicotine (100 µM) and transmural nerve stimulation (TNS, 8 Hz) induce NO-mediated dilation in the arteries. Nicotine-induced vasodilations were concentration-dependently inhibited by huperzine A and donepezil, with the former being 30 fold less potent than the latter. Both cholinesterase inhibitors weakly and equally decreased TNS-elicited nitrergic vasodilations. Neither huperzine A nor donepezil affected isoproterenol (a ß adrenoceptor-agonist)- or sodium nitroprusside (a NO donor)-induced vasodilation. Further, huperzine A was less potent than donepezil in inhibiting nicotine-elicited calcium influxes in rodent superior cervical ganglionic neurons and inward currents in α7- and α3ß2-nicotinic acetylcholine receptor-expressing Xenopus oocytes. In conclusion, huperzine A may exert less harmful effect over donepezil on maintaining brainstem circulation and on the nicotinic acetylcholine receptor-associated cognition deficits during treatment for Alzheimer's disease.
Assuntos
Artéria Basilar/fisiopatologia , Inibidores da Colinesterase/efeitos adversos , Disfunção Cognitiva/induzido quimicamente , Neurônios Nitrérgicos/efeitos dos fármacos , Vasodilatação/efeitos dos fármacos , Alcaloides/administração & dosagem , Alcaloides/efeitos adversos , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/fisiopatologia , Animais , Artéria Basilar/efeitos dos fármacos , Artéria Basilar/inervação , Tronco Encefálico/irrigação sanguínea , Tronco Encefálico/efeitos dos fármacos , Tronco Encefálico/patologia , Tronco Encefálico/fisiopatologia , Cálcio/metabolismo , Inibidores da Colinesterase/administração & dosagem , Disfunção Cognitiva/fisiopatologia , Donepezila/administração & dosagem , Donepezila/efeitos adversos , Relação Dose-Resposta a Droga , Humanos , Modelos Animais , Nicotina/metabolismo , Neurônios Nitrérgicos/metabolismo , Neurônios Nitrérgicos/fisiologia , Oócitos , Técnicas de Patch-Clamp , Ratos , Receptores Nicotínicos/metabolismo , Sesquiterpenos/administração & dosagem , Sesquiterpenos/efeitos adversos , Suínos , Transmissão Sináptica/efeitos dos fármacos , Vasodilatação/fisiologia , Xenopus laevisRESUMO
BACKGROUND: To evaluate the short-term efficacy, long-term efficacy, and adverse events (AEs) of elemene plus transcatheter arterial chemoembolization (TACE) in comparison with TACE alone for the treatment of hepatocellular carcinoma (HCC). METHODS: PubMed, EMBASE, the Cochrane Library, the Chinese Scientific Journal Full-text Database, Wanfang Data, CBM, and VIP were searched by 2 reviewers using the same search strategy for clinical studies on elemene plus TACE in the treatment of HCC. These articles were screened according to pre-established inclusion and exclusion criteria, and the qualities of the included studies were assessed using the Newcastle-Ottawa scale. The primary outcomes were the objective response rate (ORR), the 1-year survival rate and AEs. Review Manager 5.3 and Stata 15.0 were used for the meta-analysis. RESULTS: A total of 10 studies involving 543 patients (TACE + elemeneâ=â277, TACE aloneâ=â266) were included. The results showed that the ORR was significantly improved in the combined treatment group compared to the TACE alone group (odds ratio [OR]â=â2.72, 95% confidence interval [CI]: 1.84-4.00, Pâ<â.05). TACE + elemene significantly increased the 1-year survival rate (ORâ=â2.79, 95% CI: 1.58-4.95, Pâ<â.05). We also found no significant difference in gastrointestinal reactions (ORâ=â0.97, 95% CI: 0.57-1.64, Pâ=â.90), fever (ORâ=â0.80, 95% CI: 0.37-1.71, Pâ=â.56), or bone marrow suppression (ORâ=â0.73, 95% CI: 0.44-1.22, Pâ=â.23) between the 2 groups. CONCLUSION: Based on current findings, TACE + elemene injection may improve the ORR and the 1-year survival rate for HCC patients compared to TACE alone. Arterial perfusion may be superior to intravenous guttae.
Assuntos
Antineoplásicos/uso terapêutico , Carcinoma Hepatocelular/tratamento farmacológico , Quimioembolização Terapêutica/métodos , Neoplasias Hepáticas/tratamento farmacológico , Sesquiterpenos/uso terapêutico , Antineoplásicos/administração & dosagem , Antineoplásicos/efeitos adversos , Cateterismo , Quimioembolização Terapêutica/efeitos adversos , Humanos , Injeções Intra-Arteriais , Sesquiterpenos/administração & dosagem , Sesquiterpenos/efeitos adversosRESUMO
Cancer is still a major risk factor to public health globally, causing approximately 9.8 million deaths worldwide in 2018. Despite advances in conventional treatment modalities for cancer treatment, there are still few effective therapies available due to the lack of selectivity, adverse side effects, non-specific toxicities, and tumour recurrence. Therefore, there is an immediate need for essential alternative therapeutics, which can prove to be beneficial and safe against cancer. Various phytochemicals from natural sources have been found to exhibit beneficial medicinal properties against various human diseases. Zerumbone is one such compound isolated from Zingiber zerumbet Smith that possesses diverse pharmacological properties including those of antioxidant, antibacterial, antipyretic, anti-inflammatory, immunomodulatory, as well as anti-neoplastic. Zerumbone has shown its anti-cancer effects by causing significant suppression of proliferation, survival, angiogenesis, invasion, and metastasis through the molecular modulation of different pathways such as NF-κB, Akt, and IL-6/JAK2/STAT3 (interleukin-6/janus kinase-2/signal transducer and activator of transcription 3) and their downstream target proteins. The current review briefly summarizes the modes of action and therapeutic potential of zerumbone against various cancers.
Assuntos
Antineoplásicos/administração & dosagem , Sesquiterpenos/administração & dosagem , Zingiberaceae/química , Antineoplásicos/efeitos adversos , Apoptose/efeitos dos fármacos , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Humanos , Interleucina-6/metabolismo , Janus Quinase 2/metabolismo , Estrutura Molecular , Fator de Transcrição STAT3/efeitos dos fármacos , Sesquiterpenos/efeitos adversos , Transdução de Sinais , Fator de Transcrição RelA/efeitos dos fármacosRESUMO
In folklore medicine, the plant Emilia sonchifolia, belonging to the family Asteraceae, is used for treating tumour and inflammation. In our previous studies, we have done a thorough phytochemical investigation of E. sonchifolia with a report on its potent antimetastatic activity. Further, we isolated and characterised its active fraction (AFES) containing the major compound γ-humulene with an evaluation of the antiangiogenic effect of AFES (5 mg/kg b.wt.). In the first part of the present study, AFES in different concentrations was used for the assessment of its possible anti-inflammatory effect employing three in vivo inflammatory models. Further using the most effective concentration of AFES 5 mg/kg b.wt, its effect on proinflammatory cytokine levels was recorded along with a confirmatory gene expression analysis. The results manifested with a reduction in the paw oedema significantly decreased levels of proinflammatory cytokines, C-reactive protein, nitric oxide and also there was an efficient downregulation of cyclooxygenase-2 and inducible nitric oxide. Urotoxicity is one of the major side effects of conventional chemotherapy. So in the second part of the study, we used AFES in combination with the conventional therapeutic agent cyclophosphamide in vivo in mice. The effect of AFES on urotoxicity was assessed from various biochemical parameters, cytokine markers and finally with a histopathology of the bladder. The current study revealed the protective effects of AFES, implicating reduced levels of urea nitrogen, by revamping of glutathione and marker cytokine levels towards positive amelioration. The results obtained altogether proved the safeguarding effect of AFES in murine experimental models.
Assuntos
Anti-Inflamatórios/farmacologia , Asteraceae/química , Sesquiterpenos/efeitos adversos , Sesquiterpenos/farmacologia , Animais , Proteína C-Reativa/metabolismo , Linhagem Celular , Citocinas/metabolismo , Edema/tratamento farmacológico , Edema/metabolismo , Inflamação/tratamento farmacológico , Inflamação/metabolismo , Masculino , Medicina Tradicional/métodos , Camundongos , Camundongos Endogâmicos BALB C , Sesquiterpenos Monocíclicos , Óxido Nítrico/metabolismo , Extratos Vegetais/farmacologiaRESUMO
BACKGROUND/AIMS: ß-Elemene is a bioactive sesquiterpene compound that exhibits a potent anti-tumor effect and is used in various clinical applications. However, little is known about its effect on the male reproductive system. The objective of this study was to investigate the in vitro actions of ß-elemene on human sperm function and elucidate the underlying mechanism. METHODS: The cytotoxicity of ß-elemene toward MCF-10A, MDA-MD-231, and A549 cells was evaluated with cell proliferation and colony formation assays. Additionally, human sperm were treated with different concentrations (0, 10, 20, 40, 80, 160, and 320 µM) of ß-elemene in vitro. The characteristics in human sperm essential for fertilization, including vitality, motility, capacitation, acrosome reaction, responsiveness to progesterone, and intracellular calcium concentration ([Ca2+]i) were examined with a computer-assisted sperm analysis system, chlortetracycline staining, and a fluorescent Ca2+ indicator. RESULTS: A comprehensive evaluation of sperm motility, especially hyperactivated motility, revealed that treatments with 40-320 µM ß-elemene decreased human sperm vitality, motility (total motility, progressive motility, and curvilinear velocity), and penetrating ability in a dose-dependent manner, but were non-toxic or minimally toxic toward MCF-10A, MDA-MD-231, and A549 cells. Although 10 and 20 µM ß-elemene did not affect sperm vitality and motility, these concentrations increased the spontaneous acrosome reaction and inhibited progesterone-induced sperm functions by affecting sperm [Ca2+]i. CONCLUSION: These results suggest that ß-elemene inhibits human sperm function by affecting sperm vitality and [Ca2+]i. These observations must be considered when using ß-elemene to treat cancer patients who may wish to preserve their fertility.
Assuntos
Antineoplásicos/efeitos adversos , Cálcio/metabolismo , Sobrevivência Celular/efeitos dos fármacos , Sesquiterpenos/efeitos adversos , Espermatozoides/efeitos dos fármacos , Antineoplásicos/farmacologia , Linhagem Celular Tumoral , Humanos , Masculino , Neoplasias/tratamento farmacológico , Sesquiterpenos/farmacologia , Motilidade dos Espermatozoides/efeitos dos fármacos , Espermatozoides/citologiaRESUMO
OBJECTIVE: Elemene is widely used to treat malignant pleural effusion in China. This meta-analysis aimed to evaluate the efficacy and safety of elemene in treating malignant pleural effusion. METHODS: Electronic databases including Pubmed, the Cochrane Library, Embase and Chinese biomedical literature database were searched until March 2017. Clinical controlled trials (CCTs) assessing the efficacy and safety of elemene in the treatment of malignant pleural effusion were included. The quality of the included studies was evaluated using the quality evaluation criteria of the Cochrane Handbook version 5.1.0. RESULTS: A total of 46 CCTs were included, with 2992 patients. Results of meta-analysis showed that elemene significantly improved the overall response rate (ORR) in controlling malignant pleural effusion (risk ratio [RR]â=â1.16; 95% CI: 1.08-1.23; Pâ<â.05). Subgroup results showed that the ORR of elemene in the treatment of lung cancer patients with malignant pleural effusion (RRâ=â1.20, 95% CI: 1.07-1.34; Pâ<â.05) was higher than that of other cancers (RRâ=â1.14, 95% CI: 1.05-1.23; Pâ<â.05). Meanwhile, elemene did not significantly increase the incidences of chest pain and fever (Pâ>â.05). CONCLUSION: Elemene is suggested to have the ability of improving the treatment outcome of malignant pleural effusion with acceptable safety.
Assuntos
Medicamentos de Ervas Chinesas/uso terapêutico , Derrame Pleural Maligno/tratamento farmacológico , Sesquiterpenos/uso terapêutico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias/complicações , Sesquiterpenos/efeitos adversos , Resultado do Tratamento , Adulto JovemRESUMO
Cancer is one of the most dangerous diseases that are rapidly increasing globally. After heart disease, it is the second leading cause of death, accounting for seven million deaths each year. Chemotherapy is the use of cytotoxic drugs on cancer cells. But the use of common chemotherapy drugs poses a problem due their high side effects and low efficacy. As a result, efforts are on to find new potent compounds with low side effects. The compounds extracted from plants have been studied in this regard due to their prevalence. Sesquiterpene lactones are a group of natural compounds that were first detected in Asteraceae dark plants. These compounds exercise their effects by reacting with functional groups available on proteins and enzymes, especially the thiol group. Owing to the high side effects as an antitumor synthetic drugs, efforts are being made to find drugs with high efficiency and low side effects. Their high structural ranges have attracted the attention of many researchers as a potential source of new anticancer drugs.
Assuntos
Antineoplásicos Fitogênicos/uso terapêutico , Lactonas/uso terapêutico , Neoplasias/tratamento farmacológico , Sesquiterpenos/uso terapêutico , Animais , Antineoplásicos Fitogênicos/efeitos adversos , Antineoplásicos Fitogênicos/química , Antioxidantes/uso terapêutico , Humanos , Lactonas/efeitos adversos , Lactonas/química , Estrutura Molecular , Neoplasias/metabolismo , Neoplasias/patologia , Estresse Oxidativo/efeitos dos fármacos , Sesquiterpenos/efeitos adversos , Sesquiterpenos/química , Relação Estrutura-AtividadeRESUMO
BACKGROUND: Malignant pleural effusion (MPE) refers to pleural effusion which arises from primary malignant tumor of pleura or other pleural metastatic tumors. Injection of elemene in chest makes good effect on the treatment of MPE, and is widely used in clinic. Adverse effects also exist, but the severe adverse effects and relevant managements are rarely reported. The aim of this study is to observe the adverse reactions induced by the treatment of malignant pleural effusion through elemene injection and to explore the solutions. METHODS: A retrospective analysis was made on 14 cases of patients receiving intra-pleural injections with elemene, and the incidence of severe adverse reactions of 7 cases were disscussed in detail. RESULTS: Most of the severe adverse reactions caused by elemene were severe chest pain, dyspnea, wheezing, clouding of consciousness and coagulopathy. CONCLUSIONS: Strict screening, full preprocessing and close monitoring are necessary to prevent serious adverse reactions caused by elemene injection in the treatment of malignant pleural effusion.
Assuntos
Sesquiterpenos/administração & dosagem , Sesquiterpenos/efeitos adversos , Tórax , Idoso , Feminino , Humanos , Injeções , Masculino , Pessoa de Meia-Idade , Derrame Pleural Maligno/tratamento farmacológico , Estudos Retrospectivos , Sesquiterpenos/uso terapêuticoRESUMO
AIMS: There are no treatments for the extreme hyperphagia and obesity in Prader-Willi syndrome (PWS). The bestPWS clinical trial assessed the efficacy, safety and tolerability of the methionine aminopeptidase 2 (MetAP2) inhibitor, beloranib. MATERIALS AND METHODS: Participants with PWS (12-65 years old) were randomly assigned (1:1:1) to biweekly placebo, 1.8 mg beloranib or 2.4 mg beloranib injection for 26 weeks at 15 US sites. Co-primary endpoints were the changes in hyperphagia [measured by Hyperphagia Questionnaire for Clinical Trials (HQ-CT); possible score 0-36] and weight by intention-to-treat. ClinicalTrials.gov registration: NCT02179151. RESULTS: One-hundred and seven participants were included in the intention-to-treat analysis: placebo (n = 34); 1.8 mg beloranib (n = 36); or 2.4 mg beloranib (n = 37). Improvement (reduction) in HQ-CT total score was greater in the 1.8 mg (mean difference -6.3, 95% CI -9.6 to -3.0; P = .0003) and 2.4 mg beloranib groups (-7.0, 95% CI -10.5 to -3.6; P = .0001) vs placebo. Compared with placebo, weight change was greater with 1.8 mg (mean difference - 8.2%, 95% CI -10.8 to -5.6; P < .0001) and 2.4 mg beloranib (-9.5%, 95% CI -12.1 to -6.8; P < .0001). Injection site bruising was the most frequent adverse event with beloranib. Dosing was stopped early due to an imbalance in venous thrombotic events in beloranib-treated participants (2 fatal events of pulmonary embolism and 2 events of deep vein thrombosis) compared with placebo. CONCLUSIONS: MetAP2 inhibition with beloranib produced statistically significant and clinically meaningful improvements in hyperphagia-related behaviours and weight loss in participants with PWS. Although investigation of beloranib has ceased, inhibition of MetAP2 is a novel mechanism for treating hyperphagia and obesity.
Assuntos
Aminopeptidases/antagonistas & inibidores , Depressores do Apetite/uso terapêutico , Cinamatos/uso terapêutico , Cicloexanos/uso terapêutico , Compostos de Epóxi/uso terapêutico , Glicoproteínas/antagonistas & inibidores , Hiperfagia/prevenção & controle , Obesidade/prevenção & controle , Síndrome de Prader-Willi/tratamento farmacológico , Inibidores de Proteases/uso terapêutico , Sesquiterpenos/uso terapêutico , Adolescente , Adulto , Aminopeptidases/metabolismo , Depressores do Apetite/administração & dosagem , Depressores do Apetite/efeitos adversos , Índice de Massa Corporal , Cinamatos/administração & dosagem , Cinamatos/efeitos adversos , Cicloexanos/administração & dosagem , Cicloexanos/efeitos adversos , Relação Dose-Resposta a Droga , Método Duplo-Cego , Término Precoce de Ensaios Clínicos , Compostos de Epóxi/administração & dosagem , Compostos de Epóxi/efeitos adversos , Feminino , Glicoproteínas/metabolismo , Humanos , Hiperfagia/etiologia , Hiperfagia/fisiopatologia , Análise de Intenção de Tratamento , Masculino , Metionil Aminopeptidases , Obesidade/etiologia , Síndrome de Prader-Willi/fisiopatologia , Inibidores de Proteases/administração & dosagem , Inibidores de Proteases/efeitos adversos , Sesquiterpenos/administração & dosagem , Sesquiterpenos/efeitos adversos , Índice de Gravidade de Doença , Trombose Venosa/induzido quimicamente , Trombose Venosa/fisiopatologia , Redução de Peso/efeitos dos fármacos , Adulto JovemRESUMO
93 patients with LABC (T2N1-2M0, T3N0-2M0) at the age from 35 to 75 years were included in the trial. With 2 stage - 60 patients, with the third stage - 33 patients. All patients were randomized into 3 groups: The I control group (n=36) received 4 courses of neoadjuvant chemotherapy according to AC-protocol (doxorubicin 50 mg/m2, cyclophosphan-500 mg/m2 on day 1, repeated every three weeks) followed by radical mastectomy, 4 courses of adjuvant chemotherapy (ÐС), radiotherapy and hormone therapy if indicated. II investigative group (n=30) received the same CTX but in combination with Arglabin at a dose of 370 mg/m2 for 7 days. III investigative group (n=27) received Arglabin as monotherapy. The clinical efficacy of neoadjuvant chemotherapy according to the scheme of AC and AC + arglabin was the same and significantly exceeded Arlabine monotherapy. There was no statistically significant difference in pathological response in patients of all three groups. Arglabin has very low toxicity and eliminates the toxic effects of standard chemotherapy.
Assuntos
Antineoplásicos/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Sesquiterpenos/uso terapêutico , Adulto , Idoso , Antineoplásicos/efeitos adversos , Neoplasias da Mama/patologia , Humanos , Metástase Linfática , Pessoa de Meia-Idade , Terapia Neoadjuvante , Período Pré-Operatório , Sesquiterpenos/efeitos adversos , Sesquiterpenos de GuaianoRESUMO
Enterocytozoon bieneusi microsporidiosis is an emerging disease in immunocompromised patients. We report 2 cases of this disease in allogeneic hematopoietic stem cell transplant patients successfully treated with fumagillin. Thrombocytopenia occurred but without major adverse events. Modifications of immunosuppression could be avoided when E. bieneusi is rapidly identified and fumagillin therapy is started promptly.
Assuntos
Antifúngicos/administração & dosagem , Cicloexanos/administração & dosagem , Enterocytozoon/efeitos dos fármacos , Ácidos Graxos Insaturados/administração & dosagem , Transplante de Células-Tronco Hematopoéticas , Leucemia Mieloide/imunologia , Microsporidiose/tratamento farmacológico , Adulto , Antifúngicos/efeitos adversos , Cicloexanos/efeitos adversos , Enterocytozoon/patogenicidade , Enterocytozoon/fisiologia , Ácidos Graxos Insaturados/efeitos adversos , Feminino , Humanos , Imunossupressores/uso terapêutico , Leucemia Mieloide/patologia , Leucemia Mieloide/terapia , Masculino , Microsporidiose/diagnóstico , Microsporidiose/microbiologia , Pessoa de Meia-Idade , Ácido Micofenólico/uso terapêutico , Contagem de Plaquetas , Prednisona/uso terapêutico , Sesquiterpenos/administração & dosagem , Sesquiterpenos/efeitos adversos , Trombocitopenia/induzido quimicamente , Resultado do TratamentoRESUMO
Bovine enzootic haematuria (BEH) is a debilitating disease of cattle caused by chronic ingestion of bracken fern. Control of BEH is difficult when bracken fern is abundant and fodder resources are limited. To fill a significant knowledge gap on modifiable risk factors for BEH, we conducted a case-control study to identify cattle management practices associated with BEH in the Bhutanese cattle population. A case-control study involving 16 of the 20 districts of Bhutan was carried out between March 2012 and June 2014. In Bhutan sodium acid phosphate and hexamine (SAP&H) is used to treat BEH-affected cattle. All cattle greater than three years of age and treated with SAP&H in 2011 were identified from treatment records held by animal health offices. Households with at least one SAP&H-treated cattle were defined as probable cases. Probable case households were visited and re-classified as confirmed case households if the BEH status of cattle was confirmed following clinical examination and urinalysis. Two control households were selected from the same village as the case household. Households were eligible to be controls if: (1) householders reported that none of their cattle had shown red urine during the previous five years, and (2) haematuria was absent in a randomly selected animal from the herd following clinical examination. Details of cattle management practices were elicited from case and control householders using a questionnaire. A conditional logistic regression model was used to quantify the association between exposures of interest and household BEH status. A total of 183 cases and 345 controls were eligible for analysis. After adjusting for known confounders, the odds of free-grazing for two and three months in the spring were 3.81 (95% CI 1.27-11.7) and 2.28 (95% CI 1.15-4.53) times greater, respectively, in case households compared to controls. The odds of using fresh fern and dry fern as bedding in the warmer months were 2.05 (95% CI 1.03-4.10) and 2.08 (95% CI 0.88-4.90) times greater, respectively, in cases compared to controls. This study identified two husbandry practices that could be modified to reduce the risk of BEH in Bhutanese cattle. Avoiding the use of bracken fern as bedding is desirable, however, if fern is the only available material, it should be harvested during the colder months of the year. Improving access to alternative fodder crops will reduce the need for householders to rely on free-grazing as the main source of metabolisable energy for cattle during the spring.
Assuntos
Doenças dos Bovinos/epidemiologia , Doenças dos Bovinos/etiologia , Gleiquênias/intoxicação , Hematúria/veterinária , Indanos/efeitos adversos , Intoxicação por Plantas/veterinária , Sesquiterpenos/efeitos adversos , Criação de Animais Domésticos , Animais , Butão/epidemiologia , Estudos de Casos e Controles , Bovinos , Doenças dos Bovinos/prevenção & controle , Hematúria/epidemiologia , Hematúria/etiologia , Hematúria/prevenção & controle , Abrigo para Animais , Modelos Logísticos , Fatores de Risco , Águas Salinas , Inquéritos e QuestionáriosRESUMO
Artemisia annua L. is a Chinese medicinal plant, which is used throughout Asia and Africa as tea or press juice to treat malaria. The bioactivity of its chemical constituent, artemisinin is, however, much broader. We and others found that artemisinin and its derivatives also exert profound activity against tumor cells in vitro and in vivo. Should artemisinin-type drugs be applied routinely in clinical oncology in the future, then it should probably be as part of combination therapy regimens rather than as monotherapy. In the present review, I give a comprehensive overview on synergistic and additive effects of artemisinin-type drugs in combination with different types of cytotoxic agents and treatment modalities: (a) standard chemotherapeutic drugs, (b) radiotherapy and photodynamic therapy, (c) established drugs for other indications than cancer, (d) novel synthetic compounds, (e) natural products and natural product derivatives, (f) therapeutic antibodies and recombinant proteins, and (g) RNA interference. I also summarize the activity of artemisinin-type drugs towards multidrug-resistant cells and tumor cells with other drug resistance phenomena. As synergistic interactions may not only occur in tumor cells, toxic reactions in normal cells (hepatotoxicity, drug interactions) were also considered. This review summarizes the scientific literature of more than 20years until the end of 2016.
Assuntos
Antineoplásicos Fitogênicos/uso terapêutico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Artemisininas/uso terapêutico , Drogas em Investigação/uso terapêutico , Neoplasias/tratamento farmacológico , Animais , Antineoplásicos Fitogênicos/efeitos adversos , Antineoplásicos Fitogênicos/farmacologia , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Artemisininas/efeitos adversos , Artemisininas/farmacologia , Produtos Biológicos/efeitos adversos , Produtos Biológicos/farmacologia , Produtos Biológicos/uso terapêutico , Linhagem Celular Tumoral , Doença Hepática Induzida por Substâncias e Drogas/etiologia , Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle , Terapia Combinada/efeitos adversos , Interações Medicamentosas , Resistência a Múltiplos Medicamentos , Resistencia a Medicamentos Antineoplásicos , Sinergismo Farmacológico , Drogas em Investigação/efeitos adversos , Drogas em Investigação/farmacologia , Humanos , Neoplasias/terapia , Sesquiterpenos/efeitos adversos , Sesquiterpenos/farmacologia , Sesquiterpenos/uso terapêuticoRESUMO
AIMS: Hypothalamic injury-associated obesity (HIAO) results from damage to the hypothalamus that often occurs with surgical removal/radiation therapy of tumours in the hypothalamic region, such as craniopharyngioma. There is currently no rigorously studied pharmaceutical treatment for the intractable weight gain and cardiometabolic consequences that occur in patients with HIAO. We aimed to assess efficacy, safety and tolerability of beloranib treatment for 4 to 8 weeks in patients with HIAO. MATERIALS AND METHODS: This Phase 2a, double-blind, placebo-controlled study included 14 patients with HIAO, randomized to receive beloranib 1.8 mg or placebo subcutaneously twice weekly for 4 weeks with an optional 4-week open-label extension in which all patients received beloranib. The primary endpoint was change in weight from baseline to Week 4. RESULTS: Participants were 64% female, with a mean (SD) age of 32 (9) years, BMI of 43 (7) kg/m2 and weight of 126 (22) kg. Compared with placebo (N = 4), beloranib 1.8 mg (N = 8) resulted in a mean (95% CI) difference in weight of -3.2 (-5.4, -0.9) kg after 4 weeks. Weight loss continued through the 8 weeks in patients randomized to beloranib (mean -6.2 [-8.2, -4.1] kg). Beloranib treatment was associated with improvements in high-sensitivity CRP. Adverse events were mild to moderate. No patients who received beloranib discontinued treatment. CONCLUSION: Beloranib treatment resulted in progressive weight loss in patients with HIAO that was comparable to that observed with beloranib in patients with exogenous obesity. These findings indicate a novel mechanism for treating obesity in patients with HIAO.
Assuntos
Aminopeptidases/antagonistas & inibidores , Depressores do Apetite/uso terapêutico , Doenças Cardiovasculares/prevenção & controle , Cinamatos/uso terapêutico , Cicloexanos/uso terapêutico , Compostos de Epóxi/uso terapêutico , Glicoproteínas/antagonistas & inibidores , Hipotálamo/lesões , Síndrome Metabólica/prevenção & controle , Obesidade Mórbida/tratamento farmacológico , Sesquiterpenos/uso terapêutico , Adulto , Aminopeptidases/metabolismo , Depressores do Apetite/administração & dosagem , Depressores do Apetite/efeitos adversos , Biomarcadores/sangue , Índice de Massa Corporal , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/etiologia , Cinamatos/administração & dosagem , Cinamatos/efeitos adversos , Estudos de Coortes , Cicloexanos/administração & dosagem , Cicloexanos/efeitos adversos , Método Duplo-Cego , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/efeitos adversos , Inibidores Enzimáticos/uso terapêutico , Compostos de Epóxi/administração & dosagem , Compostos de Epóxi/efeitos adversos , Feminino , Seguimentos , Glicoproteínas/metabolismo , Humanos , Injeções Subcutâneas , Masculino , Síndrome Metabólica/epidemiologia , Síndrome Metabólica/etiologia , Metionil Aminopeptidases , Obesidade Mórbida/sangue , Obesidade Mórbida/etiologia , Obesidade Mórbida/fisiopatologia , Estudo de Prova de Conceito , Risco , Sesquiterpenos/administração & dosagem , Sesquiterpenos/efeitos adversos , Redução de Peso/efeitos dos fármacos , Adulto JovemRESUMO
In this article, some aspects of sandalwood oil, ylang-ylang oil, and jasmine absolute are discussed including their botanical origin, uses of the plants and the oils and absolute, chemical composition, contact allergy to and allergic contact dermatitis from these essential oils and absolute, and their causative allergenic ingredients.
Assuntos
Cananga/química , Dermatite Alérgica de Contato/etiologia , Jasminum/química , Óleos Voláteis/farmacologia , Óleos de Plantas/farmacologia , Pele/efeitos dos fármacos , Aromaterapia , Humanos , Óleos Voláteis/efeitos adversos , Testes do Emplastro , Óleos de Plantas/efeitos adversos , Sesquiterpenos/efeitos adversos , Sesquiterpenos/farmacologiaAssuntos
Dor Abdominal/tratamento farmacológico , Bálsamos/efeitos adversos , Dermatite de Contato/diagnóstico , Ferula , Flatulência/tratamento farmacológico , Óleos Voláteis/efeitos adversos , Dor Abdominal/diagnóstico , Bálsamos/administração & dosagem , Cumarínicos/administração & dosagem , Cumarínicos/efeitos adversos , Flatulência/diagnóstico , Humanos , Lactente , Óleos Voláteis/administração & dosagem , Sesquiterpenos/administração & dosagem , Sesquiterpenos/efeitos adversosRESUMO
Allergic contact dermatitis is a common skin disease, which affects approximately 20% of the population. This reaction may present with several clinical manifestations. Erythema multiforme-like allergic contact dermatitis is a rare type of non-eczematous contact dermatitis, which may lead to difficulty in diagnosis.Essential oil of Laurus nobilis is widely used in massage therapy for antiinflammatory and analgesic effects. Laurus nobilis induced contact dermatitis has been reported in the literature but an erythema multiforme-like presentation is rare.
Assuntos
Dermatite Alérgica de Contato/etiologia , Eritema Multiforme/etiologia , Óleos de Plantas/efeitos adversos , Sesquiterpenos/efeitos adversos , Dermatite Alérgica de Contato/patologia , Eritema Multiforme/patologia , Humanos , Masculino , Massagem , Pessoa de Meia-IdadeRESUMO
Avarol is a sesquiterpenoid hydroquinone with potent cytotoxicity. Although resolving endoplasmic reticulum (ER) stress is essential for intracellular homeostasis, erratic or excessive ER stress can lead to apoptosis. Here, we reported that avarol selectively induces cell death in pancreatic ductal adenocarcinomas (PDAC), which are difficult to treat owing to the availability of few chemotherapeutic agents. Analyses of the molecular mechanisms of avarol-induced apoptosis indicated upregulation of ER stress marker BiP and ER stress-dependent apoptosis inducer CHOP in PDAC cells but not in normal cells, suggesting that avarol selectively induces ER stress responses. We also showed that avarol activated the PERK-eIF2α pathway but did not affect the IRE1 and ATF6 pathways. Moreover, CHOP downregulation was significantly suppressed by avarol-induced apoptosis. Thus, the PERK-eIF2α-CHOP signaling pathway may be a novel molecular mechanism of avarol-induced apoptosis. The present data indicate that avarol has potential as a chemotherapeutic agent for PDAC and induces apoptosis by activating the PERK-eIF2α pathway.